7R90 Stock Chart & Stats
€2.62
€0.00(0.00%)
At close: 4:00 PM EDT
€2.62
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.63 - €5.65
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€11.61M
Enterprise Value€8.84
Total Cash (Recent Filing)€6.20M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.23
Shares Outstanding20,234,993
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Flexible Equity Financing FacilityA committed multi-year $50M equity facility materially expands financing optionality and provides runway to advance platform builds and partnerships. Over the medium term this reduces immediate insolvency risk and supports continued R&D and go-to-market execution if draws are managed.
Low Financial Leverage And Larger Equity BaseMinimal debt and a materially improved equity base give structural financial flexibility: lower interest burden, greater capacity to raise additional equity, and less short-term solvency pressure, enabling funding of strategic transitions without immediate refinancing risk.
Platform And Infrastructure Product LaunchesShifting to a marketplace and autonomous-asset infrastructure targets durable, scalable revenue rails. Platform models can generate network effects and recurring fees across B2B and B2C segments; success would structurally alter revenue prospects versus previous biotech exposure.
Bears Say
No Revenue And Widening LossesPersistent pre-revenue status with materially larger TTM losses indicates the business model has not yet generated commercial traction. Over months this erodes equity, increases dependence on external capital, and raises the bar for successful monetization of new platform initiatives.
Sustained Negative Operating Cash FlowOngoing cash burn forces reliance on financing and limits self-funding of growth. Even with financing capacity, repeated draws can dilute shareholders, constrain strategic optionality, and create pressure to cut investments or pivot before platforms scale.
Leadership Turnover And Strategic Wind-downMajor executive departures and a structured wind-down of legacy operations heighten execution risk during a critical strategic pivot. Loss of continuity, potential restructuring charges, and transition delays can slow revenue rail development and complicate delivery of platform initiatives.
AIxCrypto Holdings News
7R90 FAQ
What was AIxCrypto Holdings’s price range in the past 12 months?
AIxCrypto Holdings lowest stock price was €2.63 and its highest was €5.65 in the past 12 months.
What is AIxCrypto Holdings’s market cap?
AIxCrypto Holdings’s market cap is €11.61M.
When is AIxCrypto Holdings’s upcoming earnings report date?
AIxCrypto Holdings’s upcoming earnings report date is Aug 18, 2026 which is in 15 days.
How were AIxCrypto Holdings’s earnings last quarter?
AIxCrypto Holdings released its earnings results on May 11, 2026. The company reported -€0.684 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is AIxCrypto Holdings overvalued?
According to Wall Street analysts AIxCrypto Holdings’s price is currently Overvalued.
Does AIxCrypto Holdings pay dividends?
AIxCrypto Holdings does not currently pay dividends.
What is AIxCrypto Holdings’s EPS estimate?
AIxCrypto Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AIxCrypto Holdings have?
AIxCrypto Holdings has 20,234,993 shares outstanding.
What happened to AIxCrypto Holdings’s price movement after its last earnings report?
AIxCrypto Holdings reported an EPS of -€0.684 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AIxCrypto Holdings?
Currently, no hedge funds are holding shares in DE:7R90
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AIxCrypto Holdings
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.